Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

Фаза 2 Завершено NCT00821821

Кратко

The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.

Number of Participants That Experienced Adverse Events

87days · participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• Closed-loop Deep Brain Stimulation to Treat Refractory Neuropathic Pain — Prasad Shirvalkar, MD, PhD
• Women's Health Initiative Strong and Healthy Study — Fred Hutchinson Cancer Center
• Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke — Shionogi
• Zambia Stroke Unit Study — Johns Hopkins University
• Tracking Post-stroke Walking Improvements From the Clinic Into the Home — Western University of Health Sciences
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University

Все исследования